Data from a systematic literature review to determine the relationship between HBsAg (prevalence of HBV infection) and anti-HBc (exposure to HBV infection) in African populations.

This file set contains the metadata for an analysis of HBV sero-epidemiology data for Africa. We set out to investigate the relationship between prevalence of hepatitis B virus (HBV) infection and prevalence of exposure to infection.<br>We used HBsAg as a marker of active infection and anti-HBc as a marker of HBV exposure (including active infection, and exposed/cleared infection).<br>We gathered data from a literature review of PubMed and Web of Science searching for either “HBV antibody”, “antiHBc”, “HB core antibody”, “HBV exposure” or, “HBV prevalence” AND “Africa” or [Name of specific country]. Only papers published after the introduction of universal HBV vaccination in Africa in 1995 were included. Identified articles were reviewed to ensure both HBsAg and corresponding HBcAb prevalence for a given population were included. <br><br>Ethics permission was not required for this study,<br><b>Table 1; Meta-data extracted from studies identified in a systematic literature search for studies including anti-HBc and HBsAg prevalence data for African countries published between 1995-2019. </b>A total of 96 studies spanning 39 African countries were identified in the search, generating 109 unique data points representing independent cohorts. A PMID or DOI is provided for each manuscript. When a PMID or DOI could not be found (n=2), ISI or ISSN was provided. A key and notes on the table is given at the foot of the table. <b>Table 2: Quality assessment of the 96 studies included in the meta-analysis.</b> Studies were assessed using established guidelines from the Johanna Briggs Institute for the critical appraisal of the scientific literature (1). Complete metadata for the manuscript are available in Table 1. All studies included in this analysis assessed the prevalence of HBsAg and anti-HBc. The sample size required for each was different. Sample size was assessed using guidelines established by Naing et al, (2006) (2). Notes on the studies are given at the foot of the table. References1. Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. International Journal of Evidence-Based Healthcare. 2015;13(3):147–53.2. Naing L, Winn T, Rusli BN. Practical Issues in Calculating the Sample Size for Prevalence Studies. Archives of Orofacial Sciences. 2006;1(June 2014):9–14.

本数据集包含针对非洲乙型肝炎病毒（hepatitis B virus, HBV）血清流行病学数据分析的元数据。本研究旨在探讨乙型肝炎病毒（HBV）感染流行率与病毒感染暴露流行率之间的关联。
本研究以乙型肝炎表面抗原（HBsAg）作为现症感染的标志物，以乙型肝炎核心抗体（anti-HBc）作为HBV暴露的标志物（涵盖现症感染以及已暴露并清除病毒的感染状态）。
本研究通过对PubMed与Web of Science数据库开展文献检索以收集数据，检索式包含“HBV抗体”“antiHBc”“HB核心抗体”“HBV暴露”或“HBV流行率”，并与“非洲”或[特定国家名称]进行逻辑与组合。仅纳入1995年非洲全面推行乙型肝炎疫苗接种后发表的文献。对检索得到的文献进行筛选，确保所纳入的人群研究同时包含HBsAg与对应HBcAb的流行率数据。
本研究无需伦理审批。
**表1：1995-2019年发表的非洲国家anti-HBc与HBsAg流行率相关研究的系统文献检索元数据提取结果**
本次检索共筛选得到覆盖39个非洲国家的96项研究，共获得109个代表独立队列的唯一数据点。每篇文献均提供了PubMed编号（PMID）或数字对象标识符（DOI）；对于2篇未检索到PMID或DOI的文献，提供了ISI编号或国际标准连续出版物编号（ISSN）。该表格末尾附有图例与注释。
**表2：本荟萃分析纳入的96项研究的质量评价结果**
本研究采用约翰娜·布里格斯研究所（Johanna Briggs Institute）发布的科学文献批判性评价指南对纳入研究进行质量评估（1）。本研究的完整元数据详见表1。本次分析纳入的所有研究均对HBsAg与anti-HBc的流行率进行了评估，且各项研究的样本量要求各不相同。样本量计算采用Naing等人2006年发布的相关指南（2）。研究注释详见表格末尾。
参考文献
1. Munn Z, MClinSc SM, Lisy K, Riitano D, Tufanaru C. 报告流行率与累积发病率数据的观察性流行病学研究系统评价方法学指南. 国际循证医疗卫生期刊. 2015;13(3):147–153.
2. Naing L, Winn T, Rusli BN. 流行率研究样本量计算的实际问题. 口腔颌面科学档案. 2006;1(2014年6月):9–14.